Polar Capital’s Sage Therapeutics SAGE Stock Holding History

Polar Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-22,500	Closed	-$3.16M	–	307
2019 Q3	$3.16M	Sell	22,500 -52,500	-70%	-$8.78M	0.03%	244
2019 Q2	$13.7M	Sell	75,000 -50,000	-40%	-$8.53M	0.12%	169
2019 Q1	$19.9M	Buy	125,000 +95,000	+317%	+$13.8M	0.18%	148
2018 Q4	$2.87M	Sell	30,000 -5,000	-14%	-$572K	0.03%	227
2018 Q3	$4.94M	Sell	35,000 -40,000	-53%	-$6.17M	0.04%	217
2018 Q2	$11.7M	Buy	+75,000	New	+$11.8M	0.07%	185
2016 Q2	–	Sell	-160,000	Closed	-$5.13M	–	271
2016 Q1	$5.13M	Buy	+160,000	New	+$5.63M	0.1%	173
2015 Q3	–	Sell	-8,685	Closed	-$634K	–	284
2015 Q2	$634K	Buy	+8,685	New	+$558K	0.01%	263

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Polar Capital's SAGE Position: Q4 2019 in Review

Polar Capital sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 22,500 shares — an estimated $3.16M sold.

Polar Capital first reported a position in SAGE in Q2 2015 and held it in 8 quarters. The position peaked at $19.9M in Q1 2019. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Polar Capital reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Polar Capital sold 22,500 Sage Therapeutics shares in Q4 2019, an estimated $3.16M.
Polar Capital first reported a position in Sage Therapeutics in Q2 2015 and held it in 8 quarters.
Polar Capital's Sage Therapeutics position peaked at $19.9M in Q1 2019.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Polar Capital's 13F filing for Q4 2019, filed 14 Feb 2020.